Reports and agencies are releasing the newest problem in the worlds health as the number one issue facing this era “Antimicrobal Resistance”. In a consciously alarming report released by WHO, the agency said, “Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill.”
The spread of deadly superbugs that evade even the most powerful antibiotics is no longer a prediction but is happening right now across the world, United Nations officials said.
The CDC created the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) in 2009 with the goal of improving cooperation between the US and the EU in three key areas:
- Appropriate therapeutic use of antimicrobial drugs in medical and veterinary communities,
- Prevention of healthcare and community-associated drug-resistant infections, and
- Strategies for improving the pipeline of new antimicrobial drugs.
The World Health Organization report makes a clear case that resistance to common bacteria has reached alarming levels in many parts of the world indicating that many of the available treatment options for common infections in some settings are becoming ineffective. The technical tag name covering this new era in health is:
AMR – Antimicrobal Resistance
WHO warns, an infection with antibiotic-resistant bacteria compared to one with antibiotic-sensitive bacteria doubles a person’s risk of dying. As bacteria, fungi, viruses, and parasites grow to defy the drugs that once killed them, so grows the threat to global public health. When more and more standard treatments no longer work, largely due to overuse and misuse, infections become difficult or impossible to control. Pathogens will spread more widely, and the illnesses and hospital stays they induce will be longer and more likely to kill people.
Some estimates of the economic effects of AMR have been attempted, and the findings are disturbing in all the reports. For example, the yearly cost to the US health system alone has been estimated at US $21 to $34 billion dollars, accompanied by more than 8 million additional days in hospital.
AMR is a complex global public health challenge, and no single or simple strategy will suffice to fully contain the emergence and spread of infectious organisms that become resistant to the available antimicrobial drugs.
The development of AMR is a natural phenomenon in microorganisms, and is accelerated by the selective pressure exerted by use and misuse of antimicrobial agents in humans and animals. The current lack of new antimicrobials on the horizon to replace those that become ineffective brings added urgency to the need to protect the efficacy of existing drugs.
The CC Treatment has shown it fights infections in many areas. The CC Treatment can and will Fight the AMR, Antimicrobal Resistance war against these infections, superbugs, MRSA and the need to protect other existing drugs.